Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.

Abstract: A method is disclosed for producing a three-dimensionally deformable velour carpet for a floor trim, luggage compartment trim or load floor trim for motor vehicles, the carpet surface of which has a needled structure on the visible side, as well as the trim itself.

Abstract: The subject matter of the invention is a method for producing a three-dimensionally shaped floor panelling, luggage compartment panelling or load floor panelling for motor vehicles, the carpet surface of which has a needled structure on the visible side, as well as the panelling itself.

Abstract: A subject matter of the invention is a three-dimensionally deformable velour carpet for a floor paneling, a luggage compartment paneling or a load floor paneling of a motor vehicle, which has a needled structure on the visible side produced by structured brushes in the brush belt.

Abstract: The object of the invention is a method of manufacturing a three-dimensionally shaped floor paneling, luggage compartment paneling or load floor paneling for motor vehicles, the carpet surface of which has a needled structure on the visible side, as well as the panelings themselves.

Abstract: A pharmaceutical composition comprises multiparticulates comprising a drug, a matrix material, and swelling agent. In one aspect, the multiparticulates comprise a core comprising a drug, and a coating surrounding the core. The coating is selected from the group consisting of (i) a water-permeable, substantially drug-impermeable coating, and (ii) an anti-enteric coating.

Abstract: A highly porous, fast-disintegrating binder suitable for pharmaceutical applications and methods of making the same are disclosed, the binder comprising microporous particles of an aqueous-soluble cellulosic polymer and a wicking agent. Pharmaceutical compositions and fast-disintegrating dosage forms containing the binder are also disclosed.

Abstract: The felting needle according to the invention comprises a working part (12) with two partial sections (15, 16), each of which is preferably embodied with straight edges. The two partial sections are twisted slightly, relative to each other. Each partial section is provided with at least one ring of indentations with the indentations arranged offset to each other in axial direction. As a result, all notches are oriented uniformly in the direction of the longitudinal axis (14), despite the slight twisting of the section between the two partial sections (15, 16). The felting needle can thus be used to produce fleece materials and needle-punched felt materials, which have a nearly uniform tearing resistance in longitudinal as well as lateral direction.

Abstract: The felting needle according to the invention comprises a working part (12) with two partial sections (15, 16), each of which is preferably embodied with straight edges. The two partial sections are twisted slightly, relative to each other. Each partial section is provided with at least one ring of indentations with the indentations arranged offset to each other in axial direction. As a result, all notches are oriented uniformly in the direction of the longitudinal axis (14), despite the slight twisting of the section between the two partial sections (15, 16). The felting needle can thus be used to produce fleece materials and needle-punched felt materials, which have a nearly uniform tearing resistance in longitudinal as well as lateral direction.

Abstract: The present invention relates to the formation of microparticles from copolymers during a process involving precipitation with compressed antisolvents. The family of suitable copolymers have a semi-crystalline structure that above their glass transition temperature retain sufficient crystalline strength to form microparticles. The invention also provides systems comprising the microparticles encapsulated with a desired compound for the controlled release of the compound over a predetermined period of time.